June 12, 2024
 Case Studies

Strategic Overhaul of Project Management at Dr. Reddy's Laboratories

Dr. Reddy's Laboratories, a major Indian pharmaceutical company with a global presence, specializes in manufacturing a diverse range of medications, including Active Pharmaceutical Ingredients (APIs) and finished dosages. In 2009 Dr. Reddy's aimed to increase revenue from $1 billion to $4 billion and boost profitability from 12% to 25%.

To enhance project productivity and achieve a 95% due date performance, Dr. Reddy's decided to implement Critical Chain Project Management (CCPM) for New Product Development(NPD). However, the company faced significant challenges in managing its extensive project portfolio, which included a robust pipeline of generics, biosimilars, and new drugs under development. Before the CCPM implementation, Dr. Reddy's handled 157 projects concurrently, leading to inefficient multitasking, resource allocation issues, and a low due date performance of approximately 20%. Consequently, only 28 projects were completed annually, highlighting the need for a strategic overhaul to enhance productivity and efficiency.

Business Challenges

Dr. Reddy’s Laboratories faced the daunting task of handling a vast array of projects simultaneously. The sheer volume of 157 concurrent projects stretched their resources thin and disrupted operational efficiency. Despite meticulous planning, teams struggled to keep pace with the demands, resulting in frequent delays and significant inefficiencies in project execution.

Managing multiple projects at once posed additional challenges in effective task management and prioritization. This lack of focus caused projects to take longer and deviate from planned timelines. Additionally, allocating resources across various projects was complex. Some projects did not have enough resources, while others had too many, leading to uneven progress.

A particularly pressing issue was the company’s struggle to meet deadlines. With only 20% of projects adhering to their designated timelines, Dr. Reddy’s recognized an urgent need for enhanced project management strategies. The frequent failure to meet deadlines not only impacted project outcomes but also strained relationships with stakeholders

85% boost in project completion, from 28 to 52 completed projects without added resources

Dr. Reddy's implemented a strategic approach aimed at reducing the number of active projects and improving project management practices. Key steps included:

  1. Prioritizing Projects: Out of the 157 projects, 111 were prioritized based on a fixed criterion (filing time left, NPV, FTF, and launch dates). Of these 111 projects, only 64 were kept active (priority is fixed till release), with the remaining 47 put on hold. This allowed for a better concentration of resources on a more manageable number of projects.
  2. Reducing Integration Load: The integration load within the 64 active projects (Filing stage: 6 projects, Integration Stage: 34 projects, and Development stage: 24 projects) was reduced by 25%, effectively working on the equivalent of 48 projects.
  3. Freezing Projects: All work stopped on frozen projects with strict discipline. Resources released from frozen projects were used for adequate staffing/acceleration of open projects.
  4. Implementing Focus-&-Finish Plans: Simple ‘Focus-&-Finish’ plans with fewer than 100 tasks were created for each project, facilitating clearer project tracking and execution.
  5. Buffer Management: The buffers act as shock absorbers in case of uncertainties and ensure timely project completion despite potential delays.
  6. Full Kitting and Readiness to Start: Full kitting was enforced, ensuring that all necessary materials, facilities, and resources were in place before project commencement. The full kit included:
       
    • Materials required, facility, and resources required
    • Strategy for development, regulatory approval, and IP
    • Other approvals/licenses required to start the work

Tangible Results

1.    Project completion improved by 85% and Due Date Performance (DDP) increased from 20% to 80%.

2. Throughput Increase (FY08 – FY11):

  1. Global Generic Launches: Increased by 51%
  2. Global Generics & PSAI Fillings: Increased by 45%

3. Cycle Time Reduction: Down by 40%

Formulation Development: Decreased by 40%, leading to faster development cycles and quicker time-to-market.

Intangible Results

In addition to the tangible benefits, several intangible improvements were observed:

  1. Improved Team Synchronization: Enhanced coordination between different teams, leading to more cohesive project management and execution.
  2. Reduced Stress and Friction: Lowered stress levels among team members, reducing friction and fostering a more collaborative work environment.
  3. Enhanced Focus and Motivation: Improved focus on fewer projects led to higher quality output, boosting confidence and motivation among employees.

Conclusion

Dr. Reddy's Laboratories achieved remarkable success by adopting Critical Chain Project Management (CCPM) with the help of Realization Technologies' 'Focus-&-Finish' approach. By prioritizing projects reducing multitasking, and implementing focused plans, they achieved an 83% improvement in project completion and increased Due Date Performance from 20% to 80%. This strategic shift not only delivered tangible results like faster cycle times and increased throughput but also fostered a more collaborative and motivated work culture. Dr. Reddy's success serves as a powerful example of how strategic project management can drive exceptional outcomes and inspire industry-wide transformation.

  • Key Challenges
    • High Number of Concurrent Projects
    • Low Due Date Performance
    • Poor Multitasking
    • Resource Inefficiencies
  • Our Work 
    • Fixed project priority
    • Implemented 'Focus-&-Finish' methodology
    • Introduced effective buffer management
    • Ensured proper full kitting

  • Key Results
    • Project Completion improved by 85%
    • Due Date Performance (DDP) increased from 20% to 80%.
    • Global Generic launches increased by 51%
    • Global Generics & PSAI Fillings increased by 45%
    • Cycle time for Formulation Development decreased by 40%
       
Share: